Loading
CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.
Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Cervical Adenocarcinoma, Uveal Melanoma.
In plain words · CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.
CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.
Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system.
No product in this corpus aims at CYSLTR2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CYSLTR2: RNA tissue enhanced (placenta 22 nTPM, seminal vesicle 15 nTPM); blood lineage lineage enriched (granulocytes 90 nTPM); high antibody staining in 14 normal tissues; highest cancer staining prostate cancer (12 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Cervical cancer, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9NS75; CIViC gene CYSLTR2; IntOGen CYSLTR2; Human Protein Atlas CYSLTR2 tissue; Open Targets ENSG00000152207 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Takasaki et al, Biochem. Biophys. Res. Commun, 2000, "The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor". Source.
Sources: HGNC HGNC:18274 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NS75 (protein name, function text, keywords and locations (REST API)); CIViC gene CYSLTR2 (1 evidence items, 0 assertions, 1 variants; diseases: Cancer (GraphQL API, CC0)); IntOGen CYSLTR2 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4. Location: Cell membrane (UniProt). Locus 13q14.2 (HGNC).
RNA: tissue enhanced (placenta 22 nTPM, seminal vesicle 15 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 90 nTPM).
Medium: Adipose tissue, Bronchus, Cerebellum, Cerebral cortex, Cervix, Lung, Oral mucosa, Parathyroid gland.
RNA cancer enhanced: Kidney Renal Papillary Cell Carcinoma 20 pTPM, Thyroid Carcinoma 16 pTPM.
Medium only: skin cancer.
HPA CYSLTR2 tissue · HPA CYSLTR2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CYSLTR2" OR ABSTRACT:"CYSLTR2" OR TITLE:"cysteinyl leukotriene receptor 2" OR ABSTRACT:"cysteinyl leukotriene receptor 2" OR TITLE:"Cysteinyl leukotriene receptor 2" OR ABSTRACT:"Cysteinyl leukotriene receptor 2" OR TITLE:"CysLT 2" OR ABSTRACT:"CysLT 2" OR TITLE:"CYSLT2R" OR ABSTRACT:"CYSLT2R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CYSLTR2, not a curated reading list.
Shares Uveal melanoma, CIViC.
Shares Uveal melanoma, CIViC, IntOGen.
Shares Uveal melanoma, CIViC, IntOGen.
Shares Uveal melanoma, CIViC.
Shares Uveal melanoma, CIViC, IntOGen.